Jamie B Oughton (Jamie Oughton)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 4

Top Topics

Muscle Invasive Bladder Cancer

Top Venues

JCO precision oncology

Health technology assessment (Winchester, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Fiona J Collinson, Kara-Louise Royle, Jayne Swain, Christy Ralph, Anthony Maraveyas, Tim Eisen, Paul D Nathan, Robert J Jones, David M Meads, Tze Min Wah, Adam Martin, Janine Bestall, Christian Kelly-Morland, Christopher Linsley, Jamie B Oughton, Kevin Chan, Elisavet Theodoulou, Gustavo A Arias-Pinilla, Amy Kwan, Luis Daverede, Catherine Handforth, Sebastian Trainor, Abdulazeez Salawu, Christopher McCabe, Vicky J Goh, David L Buckley, Jenny Hewison, Walter Martin Gregory, Peter John Selby, Julia M Brown, Janet E Brown, null null
Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT. Health technology assessment (Winchester, England) 28 (45) (2024)
Katrina Walker, Samantha Hinsley, Rachel Phillip, Jamie B Oughton, Geraldine Murden, Anthony J Chalmers, Corinne Faivre-Finn, Alastair P Greystoke, Sarah R Brown, null null
Implementation of the Time-to-Event Continuous Reassessment Method Design in a Phase I Platform Trial Testing Novel Radiotherapy-Drug Combinations-CONCORDE. JCO precision oncology 6 (2022)
William J Cragg, Kathryn McMahon, Jamie B Oughton, Rachel Sigsworth, Christopher Taylor, Vicky Napp
Clinical trial recruiters' experiences working with trial eligibility criteria: results of an exploratory, cross-sectional, online survey in the UK. Trials 22 (1) (2021)
Jamie B Oughton, Heather Poad, Maureen Twiddy, Michelle Collinson, Victoria Hiley, Kathryn Gordon, Mark Johnson, Sunjay Jain, Aidan P Noon, Rohit Chahal, Matt Simms, Mohantha Dooldeniya, Phillip Koenig, Louise Goodwin, Julia M Brown, James W F Catto, null null
Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study. BMJ open 7 (8) (2017)